Quantcast

Latest chemotherapy Stories

2014-07-09 08:27:52

VANCOUVER, British Columbia and MENLO PARK, Calif., July 9, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") announced today that the company has been awarded a non-refundable financial contribution of up to CDN$194,000 from the National Research Council of Canada's Industrial Research Assistance Program (NRC-IRAP). The research funded by this award will be conducted in collaboration with the University of British Columbia, the Vancouver Prostate Centre and...

2014-07-08 23:09:40

Top mesothelioma researchers say an immunotoxin may have the power to significantly improve the effectiveness of chemotherapy in patients with malignant pleura mesothelioma. Raleigh, NC (PRWEB) July 08, 2014 According to a new NIH research study, more than three quarters of mesothelioma patients responded to chemotherapy when they were also given the anti-mesothelin immunotoxin SS1P. Click here to read Surviving Mesothelioma’s newly-posted article on how this important study may impact...

2014-07-08 23:07:23

Dalton Pharma Services signs agreement with GLyPharma Therapeutics Inc., to provide aseptic fill/finish services and analytical services for FE 203799 for cancer patients. Toronto, Ontario (PRWEB) July 08, 2014 Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical companies, today announced the company has entered into a Manufacturing Services Agreement with GLyPharma Therapeutics Inc., a specialty pharma company based in Montreal,...

2014-07-08 12:28:56

Company Continues Reinforcing Intellectual Property Protection in Additional Global Markets DALLAS and NEW YORK, July 8, 2014 /PRNewswire/ -- ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP), an emerging biopharmaceutical company, has received notification from the Hong Kong Patent Office that a patent for MuGard(TM) has been granted. The patent (HK1126134) protects a wide range of liquid formulations for the prevention and treatment of mucosal diseases and disorders. "Being awarded...

2014-07-08 08:30:12

- Findings from Phase II clinical study of investigational compound volasertib include response rate and new overall survival data. RIDGEFIELD, Conn., July 8, 2014 /PRNewswire/ -- Results from a Phase II study that compared volasertib plus low-dose cytarabine (LDAC), a form of chemotherapy, versus LDAC alone in older patients with untreated acute myeloid leukemia (AML) were published today in the American Society of Hematology journal Blood. Volasertib has not been approved by the...

2014-07-07 23:05:15

Researchers say some patients on the popular mesothelioma drug, pemetrexed, may be able to avoid the risks and discomfort of lung fluid evacuation. Raleigh, NC (PRWEB) July 07, 2014 A new Danish study suggests that the practice of draining off lung fluid to avoid pemetrexed (Alimta) toxicity may not be necessary for all patients. Surviving Mesothelioma has just posted details of the new study for mesothelioma patients and their families. Click here to read it now. Researchers at the...

2014-07-03 20:20:02

Tokyo, July 3, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received approval from the European Commission of the indication expansion of Halaven (generic name: eribulin mesylate, "eribulin") to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should...

2014-06-30 23:16:32

There is new evidence that second-line chemotherapy with a drug called gemcitabine can significantly prolong survival in people with malignant pleural mesothelioma. Raleigh, NC (PRWEB) June 30, 2014 A new study out of Turkey finds that mesothelioma patients who have second-line chemotherapy with the antimetabolite, gemcitabine (Gemzar) had a median survival rate 8 months longer than those who had only first-line chemotherapy. Surviving Mesothelioma has just posted a report on the new...

2014-06-30 12:40:20

European Society for Medical Oncology ESMO 16 World GI Congress on Gastrointestinal Cancer For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona. "The CALGB/SWOG 80405 trial was designed and formulated in 2005, and the rationale was simple: we had new drugs --bevacizumab and cetuximab-- and the study...

2014-06-27 08:26:05

OAKLAND, Calif., June 27, 2014 /PRNewswire/ -- When friends asked Warren Keppler what he wanted out of fatherhood back in 2004, his answer came naturally: "I want to run with my girls." http://photos.prnewswire.com/prnvar/20130718/SF49717LOGO That time came on a bright and chilly Thanksgiving morning, when Warren and his 8-year-old daughter, Gabi, were nervously readying to run a race -- Gabi's first ever. As they waded through the crowd, Gabi, her hair tied back into a ponytail, took in...


Latest chemotherapy Reference Libraries

Intravenous Therapy
2013-04-30 13:16:16

Intravenous therapy, commonly known as IV therapy, is known as the administration of a liquid substance directly into a vein. It is also known as drip therapy, because most often the liquid is suspended above the IV site by an infusion pump, and runs through a drip chamber, which prevents air from entering the line. IVs are the preferred method of drug administration in hospital settings because they are the fastest known route of getting medication to the body. Intravenous therapy can also...

Antiviral Chemistry & Chemotherapy
2012-04-25 09:59:26

Antiviral Chemistry & Chemotherapy is a peer-reviewed academic journal published bi-monthly by International Medical Press in London since 1997. When founded in January 1990, it was published by Blackwell Science. The current editor-in-chief is Hugh J. Field of University of Cambridge, UK. The journal publishes primary papers and reviews on all aspects of the preclinical development of antiviral agents, including their chemical synthesis, biochemistry, pharmacology, mode of action and...

More Articles (2 articles) »
Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.